ARTICLE LINKS: EFFECT OF SWITCHING DRUG FORMULATIONS FROM IMMEDIATE-RELEASE TO EXTENDED-RELEASE OROS METHYLPHENIDATE: A CHART REVIEW OF SPANISH ADULTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER.ORIGINAL RESEARCH ARTICLE CNS Drugs.2008.Josep Antoni 1 2; Bosch, Rosa 1; Castells, Xavier 1 3; Valero, Sergi 1; Nogueira, Mariana 1; Gomez, Nuria 1; Yelmo, Silvia 1; Ferrer, Marc 1 2; Martinez, Yolanda 1; Casas, Miguel 1 2 _ ABSTRACT: Background: The potential advantages of osmotic-release oral system (OROS) methylphenidate (Concerta(R)) over immediate-release (IR) methylphenidate (Rubifen(R)) in adults with attention-deficit hyperactivity disorder (ADHD), with respect to medication adherence, effectiveness and tolerability, are yet to be determined.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Methylphenidate was more effective than IR methylphenidate (p = 0.Reducing symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Stopped treatment with methylphenidate because of adverse events.The adherence, effectiveness and tolerability of OROS methylphenidate versus IR methylphenidate in adults with ADHD.Was hypothesized (after data collection) that adherence and effectiveness would be higher with OROS methylphenidate than with the IR formulation.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Methylphenidate was more effective than IR methylphenidate (p = 0.Reducing symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Mostmon adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Patients stopped treatment with methylphenidate because of adverse events.A chart review was carried out from April 2004 until April 2005.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Was more effective than IR methylphenidate (p = 0.Symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Mostmon adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Patients stopped treatment with methylphenidate because of adverse events.ADHD outpatient program in a general hospital in Spain.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Methylphenidate was more effective than IR methylphenidate (p = 0.Reducing symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Stopped treatment with methylphenidate because of adverse events.Adults with ADHD who met DSM-IV-TR criteria and who did not have any other current major psychiatric disorder.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Methylphenidate was more effective than IR methylphenidate (p = 0.Reducing symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Stopped treatment with methylphenidate because of adverse events.Were treated with IR methylphenidate three times daily for 3 months and then switched to OROS methylphenidate once daily.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Methylphenidate was more effective than IR methylphenidate (p = 0.Reducing symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Mostmon adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Patients stopped treatment with methylphenidate because of adverse events.Measure: Effectiveness was assessed by means of the ADHD rating scale-IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale at 3 months (coinciding with treatment switch) and at 6 months.Simplified Medication Adherence Questionnaire (SMAQ) was used to assess treatment adherence, and was administered at both 3 and 6 months.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Was more effective than IR methylphenidate (p = 0.Symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Mostmon adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Patients stopped treatment with methylphenidate because of adverse events.Adult ADHD patients (mean age +/- SD: 30 +/- 9.= 48 men ) were included in this study.Mean baseline ADHD-RS-IV score was 34.= 10.The mean daily dose of IR methylphenidate was 52.(SD = 13.As three divided doses.The treatment switch, the mean OROS methylphenidate daily dose was 57.(SD = 16.Once daily.From IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire.Was more effective than IR methylphenidate (p = 0.Symptoms of ADHD.Percentage of responders was 28.IR methylphenidate and 91.OROS formulation (p = 0.OROS methylphenidate was preferred by 97% of patients.Mostmon adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate).Patients stopped treatment with methylphenidate because of adverse events.Switch from IR to OROS methylphenidate was associated with an improvement in both adherence and effectiveness.Read more Death of a female addict due to heroin and cocaine overdoses: a case report with multiparameter evaluation
Get more Quality-of-life tradeoffs for hepatitis c treatment: do patients and providers agree?
